Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.46 USD
Change Today -0.02 / -0.81%
Volume 19.1K
TRGT On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

100 North Main Street

Suite 1510

Winston-Salem, NC 27101

United States

Phone: 336-480-2100

Fax: 336-480-2107

Targacept, Inc., a biopharmaceutical company, engages in the development of novel neuronal nicotinic receptors (NNR) Therapeutics to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. The company’s NNR Therapeutics selectively target a class of receptors known as neuronal nicotinic receptors, which it refers to as NNRs. TC-6499 TC-6499 is a small molecule that modulates the activity of the a3ß4 and other NNRs as an agonist the company is conducting an exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a disorder, which is often debilitating and chronic, and that slows or stops the passage of food from the stomach to the small intestine. TC-6683 TC-6683 is a novel small molecule that modulates the activity of the a4ß2 NNR. TC-5619 and TC-6987 TC-5619 and TC-6987 are novel small molecules that are highly selective for the a7 NNR. The a7 NNR has been shown to play a role in a variety of biological pathways associated with various diseases and disorders. The company completed in 2013 a Phase 2b clinical trial of TC-5619 in negative symptoms and cognitive dysfunction in schizophrenia. TC-1734 TC-1734 is a wholly-owned novel small molecule that modulates the activity of the a4ß2 NNR. In 2014, the company announced that its Phase 2b clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease did not meet its primary endpoint. The company completed in 2014 a Phase 2b clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. TC-5214 TC-5214 acts as an antagonist on the a3ß4 NNRs. The company completed in 2014 a Phase 2b clinical trial of TC-5214 in overactive bladder. Strategy The key elements of the company’s strategy are to expand its pipeline of product candidates deliberatively; and seek value for its pipeline of NNR Therapeutics. Patents and Proprietary Rights As of February 28, 2015, the company’s issued patents and pending patent applications in the United States and foreign counterparts include composition of matter coverage on various different structural families of compounds. License Agreements Pursuant to a license agreement with University of South Florida Research Foundation (USFRF), the company holds an exclusive worldwide license under patents and patent applications owned by USFRF to develop and commercialize TC-5214, mecamylamine hydrochloride and other specified compounds. The licensed patent rights include issued patents covering the pharmaceutical composition of TC-5214. Regulatory Matters The company’s product candidates must be approved by the U.S. Food and Drug Administration through the new drug application process before they may be legally marketed in the United States. History Targacept, Inc., a Delaware corporation, was founded in 1997. The company was incorporated in 1997.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRGT:US $2.46 USD -0.02

TRGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $84.51 USD -0.03
Novartis AG SFr.100.40 CHF +0.40
Pfizer Inc $36.06 USD +0.33
ProMIS Neurosciences Inc C$0.07 CAD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TRGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 393.2x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARGACEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at